Please login to the form below

Not currently logged in
Email:
Password:

multiple sclerosis drug

This page shows the latest multiple sclerosis drug news and features for those working in and with pharma, biotech and healthcare.

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Swiss pharma company also provided key updates on a number of drug candidates in its pipeline. ... growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene

Latest news

  • J&J’s MS drug ponesimod receives approval in the US J&J’s MS drug ponesimod receives approval in the US

    Johnson &Johnson’s (J&J) pharma division Janssen has announced that the US Food and Drug Administration (FDA) has approved its multiple sclerosis (MS) treatment ponesimod, under the brand name Ponvory. ... Every person with multiple sclerosis is

  • FDA advisory committee overwhelmingly votes no on Biogen's aducanumab FDA advisory committee overwhelmingly votes no on Biogen's aducanumab

    Path to approval looks increasingly difficult for potential Alzheimer’s treatment. A panel of outside experts met on Friday to examine data supporting Biogen’s new drug application for its potential ... spinal muscular atrophy drug Spinraza

  • Biogen triumphs over Mylan’s Tecfidera patent challenge Biogen triumphs over Mylan’s Tecfidera patent challenge

    Shares in Biogen skyrocketed by 32% following ruling. Biogen has scored its first major success of the year, winning a patent challenge from Mylan over its multiple sclerosis drug Tecfidera.  . ... The dispute was a significant one for Biogen –

  • Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

    BMS’ well-established anticoagulant Eliquis (apixaban) had another strong quarter with a 19% rise to just over $2bn, while multiple myeloma drug Empliciti (elotuzumab) grew by more than a third to ... $94m. Meanwhile, Caforio is confident that

  • Cosentyx, Entresto drive topline growth for Novartis in Q4 Cosentyx, Entresto drive topline growth for Novartis in Q4

    Following Cosentyx was Entresto, which grew by 71% in Q4 to $1.7bn, an impressive increase from the $430m Novartis posted for the drug in Q3. ... Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer

More from news
Approximately 0 fully matching, plus 146 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis ... The key difference between DS-8201

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    Cosentyx is the company's psoriasis treatment, and Novartis supplies the drug with an outcomes guarantee. ... The company has just secured 'Rapid Uptake' status for its multiple sclerosis drug Mavenclad via the new Accelerated Access Collaborative process

  • Death by Numbers Death by Numbers

    Not so. Take the example of this campaign for Sativex, a drug used in the treatment of Multiple Sclerosis.

  • A new dogma in HTA assessment A new dogma in HTA assessment

    Novartis faced similar difficulties in the UK when its multiple sclerosis drug Gilenya was declined by the National Institute for Health and Clinical Excellence (NICE) due to its comparator, Avonex, not ... High-end scenario planning capabilities will

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis

  • Michael Fleming joins biosimilars firm Coherus Michael Fleming joins biosimilars firm Coherus

    of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel (etanercept). ... Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple sclerosis drug Tysabri.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Covid-19: how is it affecting prescribing patterns?

    In this article, we will examine three key disease areas: COPD, rheumatoid arthritis and multiple sclerosis to determine which drug types have been the winners and losers in terms of usage ... Multiple sclerosis. Multiple sclerosis presents a more

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...